Browsing by Author Davis, Ian

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 6 of 6
Issue DateTitleAuthor(s)Citation
2011Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rateMurali, Rajmohan; Scolyer, Richard; Thompson, John; Azad, Arun; Browning, Judy; Cebon, Jonathan Simon; Davis, Ian; Deb, Siddhartha; MacGregor, Duncan P.; Pollara, Gabriele; Svobodova, Suzanne J.; Central Clinical School: Pathology; Central Clinical School: Pathology; Central Clinical School: SurgeryCancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate, European Journal of Cancer, vol.47, 3, 2011,pp 460-469
2009Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa TrialKefford, Richard (Rick); Brady, Ben; Cebon, Jonathon; Davis, Ian; Hansen, Lasse T.; Lundsgaard, Dorthe; Millward, Michael; Mouritzen, Ulrik; Skak, Kresten; Skrumsager, Birte K.; Western Clinical School: Westmead Millennium InstituteClinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial, Clinical Cancer Research, vol.15, 6,pp 2123-2129
2013Intravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: a systematic review with meta-analysisBrown, Christopher; Chalasani, Venu; Grimison, Peter; Houghton, Baerin; Patel, Manish; Stockler, Martin; Davis, Ian; Hayne, Dickon; School of Public Health: NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Surgery; School of Public Health: NH&MRC Clinical Trials CentreIntravesical chemotherapy plus bacille Calmette-Guerin in non-muscle invasive bladder cancer: a systematic review with meta-analysis, BJU International, vol.111, 6, 2013,pp 977-983
2009An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate CancerBoyer, Michael; Gurney, Howard; Davis, Ian; Kotasek, Dusan; Pezaro, Carmel; Rosenthal, Mark; Soloman, Benjamin; Toner, Guy C.; Underhill, Craig; Central Clinical School: Medicine; Western Clinical School: Medicine (Westmead)An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer, American Journal of Clinical Oncology, vol.32, 4,pp 338-341
2013Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancerChatfield, Mark; Grimison, Peter; Houghton, Baerin; Stockler, Martin; Davis, Ian; Hovey, E.; Martin, Jarad; Toner, Guy C.; Clinical Schools; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentrePatterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer, BJU International, vol.112, 2, 2013,pp E35-E43
2013Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapyBoland, Amy; Chatfield, Mark; Gebski, Val; Grimison, Peter; McDonald, Angus; Olver, Ian Norman; Stockler, Martin; Davis, Ian; Harrup, Rosemary; Kichenadasse, G; Singhal, Nimit; Thomson, Damien; Toner, Guy; Underhill, Craig; Northern Clinical School: Medicine; Clinical Schools; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: Ctr for Values Ethics & Law in Med; School of Public Health: NH&MRC Clinical Trials CentreResults of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy, Supportive Care in Cancer, vol.21, 6, 2013,pp 1561-1568